Streetbeat News

Earnings

NVO

Novo Nordisk (NYSE:NVO) has hit a 'Death Cross', a bearish technical signal, as its 50-day moving average falls below the 200-day moving average. Despite this, the company shows potential for a rebound due to strong fundamentals, including a new diabetes pill and a promising drug pipeline. Investors should watch for upcoming earnings and product developments.

Portfolio Pulse from Surbhi Jain

October 23, 2024 | 4:41 pm

LUV

Southwest Airlines is set to release its Q3 earnings report amid strategic changes and shareholder pressure. The company faces challenges with rising costs and competitive market conditions, while Elliott Investment Management pushes for leadership changes. Investors are keenly watching for signs of recovery and strategic progress.

Portfolio Pulse from Henry Khederian

October 23, 2024 | 4:36 pm

LAD

LRN

TRNR

Several consumer discretionary stocks experienced significant price movements during Wednesday's intraday session. Notable gainers included Stride (LRN) with a 34.4% increase following its Q1 earnings report, and Lithia Motors (LAD) with a 10.24% rise after releasing its Q3 earnings. On the losing side, Interactive Strength (TRNR) saw a 15.8% decline.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:31 pm

ENPH

PHUN

QBTS

SEDG

VERI

ZPTA

Several information technology stocks experienced significant price movements during Wednesday's intraday session. Notable gainers included Zapata Computing Holdings, Phunware, and D-Wave Quantum, while Veritone, SolarEdge Technologies, and Enphase Energy were among the biggest losers. Enphase Energy's decline followed the release of its Q3 earnings.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:30 pm

USNA

USANA Health Sciences shares are trading higher despite mixed Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 4:30 pm

AXP

IPAY

TGLR

American Express (AXP) has expanded its sponsorship with Formula 1 to a global level, enhancing fan experiences and hosting business customers. This move aligns with its strategy to attract Millennials and Gen Z, its fastest-growing customer segment. AXP recently became the sole owner of Swisscard and reported mixed Q3 results.

Portfolio Pulse from Lekha Gupta

October 23, 2024 | 4:22 pm

FCNCA

KRE

PNFP

SPY

WAL

JPMorgan analyst Anthony Elian is optimistic about the U.S. regional banking sector following strong Q3 earnings. Regional banks, including First Citizens BancShares, Western Alliance Bancorp, and Pinnacle Financial Partners, are expected to benefit from favorable market conditions and potential earnings growth into 2025. The SPDR Regional Banking ETF has outperformed the broader market, driven by strong net interest margins and income.

Portfolio Pulse from Piero Cingari

October 23, 2024 | 4:03 pm

HTH

Hilltop Hldgs (NYSE:HTH) is set to release its quarterly earnings report on October 24, 2024. Analysts expect an EPS of $0.35. The market is optimistic about the company surpassing estimates and providing positive guidance. In the previous quarter, despite beating EPS estimates, the stock price dropped by 1.87%. Currently, shares are trading at $30.8, up 10.65% over the past year.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:02 pm

Ryder System is set to release its quarterly earnings on October 24, 2024, with analysts expecting an EPS of $3.42. Investors are keen on not just an earnings beat but also positive future guidance. Historically, Ryder's stock price has shown minimal movement post-earnings. The stock is currently trading at $145.73, with a 52-week increase of 55.78%. Analysts rate Ryder as 'Outperform' with a price target of $155, indicating a potential 6.36% upside.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:02 pm

RMD

ResMed (NYSE:RMD) is set to release its quarterly earnings report on October 24, 2024, with analysts estimating an EPS of $2.04. Investors are keen on not just an earnings beat but also positive future guidance. ResMed's past performance shows a pattern of share price increases following earnings beats. Analysts have a Neutral consensus on ResMed with a slight potential downside in price target. ResMed shows strong revenue growth and profitability metrics compared to peers.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:02 pm